Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 363-368

  Bodar, Evelien J ^a   Simon, Anna ^a   van der Meer, Jos W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GIVINOSTAT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVOCETIRIZINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID A;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; AUTOINFLAMMATORY DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; LEUKOCYTE; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; REMISSION; SCHNITZLER SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; VOMITING;

ADULT; ANTI-INFLAMMATORY AGENTS; FEMALE; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; HYDROXAMIC ACIDS; MALE; MEVALONATE KINASE DEFICIENCY; MIDDLE AGED; PROSPECTIVE STUDIES; SCHNITZLER SYNDROME; YOUNG ADULT;

EID: 79957958329     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00039     Document Type: Article

References (22)

1. McDermott MF, et al. (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 97:133-44.
2. Masters SL, Simon A, Aksentijevich I, Kastner DL. (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27:621-68.
3. de Koning HD, et al. (2006) Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann. Rheum. Dis. 65:542-4.
4. de Koning HD, Bodar EJ, van der Meer JW, Simon A. (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin. Arthritis. Rheum. 37:137-48.
5. Drenth JPH, van Deuren M, van der Ven-Jongekrijg J, Schalkwijk CG, van der Meer JWM. (1995) Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood. 85:3586-93.
6. Frenkel J, et al. (2002) Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 46:2794-803.
7. Nowlan ML, et al. (2006) Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford). 45:31-7.
8. Rebelo SL, et al. (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfold-ing consistent with abnormal function. Arthritis Rheum. 54:2674-87.
9. Aksentijevich I, et al. (2002) De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46:3340-8.
10. Chae JJ, et al. (2003) Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell. 11:591-604.
11. Cefle A, et al. (2005) A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. Rheumatol. Int. 25:442-6.
12. Hull KM, et al. (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 81:349-68.
13. van der Hilst JC, Simon A, Drenth J P. (2005) Hereditary periodic fever and reactive amyloido-sis. Clin. Exp. Med. 5:87-98.
14. Bodar EJ, van der Hilst JC, Drenth J P, van der Meer JW, Simon A. (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 63:260-4.
15. Simon A, et al. (2004) Beneficial response to inter-leukin 1 receptor antagonist in traps. Am. J. Med. 117:208-10.
16. Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1-15.
17. Carta S, et al. (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of micro-tubules. Blood. 108:1618-26.
18. Simon A, et al. (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobu-linemia D and periodic fever syndrome. Clin. Pharmacol. Ther. 75:476-83.
19. Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353-362.
20. Hoffman HM, et al. (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 364:1779-85.
21. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452-8.
22. Vojinovic J, Damjanov N. (2011) HDAC inhibition in rheumatoid arthritis and juvenile idio-pathic arthritis. Mol. Med. 17:397-403.